PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A

Open source

DOI: 10.1186/s13058-019-1115-2
Published: 2019 Mar 11
Container: Breast cancer research : BCR
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13058-019-1115-2,
  title = {PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.},
  author = {Chia SKL and Martin M and Holmes FA and Ejlertsen B and Delaloge S and Moy B and Iwata H and von Minckwitz G and Mansi J and Barrios CH and Gnant M and Tomašević Z and Denduluri N and Šeparović R and Kim SB and Jakobsen EH and Harvey V and Robert N and Smith J 2nd and Harker G and Zhang B and Eli LD and Ye Y and Lalani AS and Buyse M and Chan A},
  year = {2019},
  journal = {Breast cancer research : BCR},
  doi = {10.1186/s13058-019-1115-2},
  url = {https://doi.org/10.1186/s13058-019-1115-2}
}

RIS

TY  - JOUR
TI  - PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
AU  - Chia SKL
AU  - Martin M
AU  - Holmes FA
AU  - Ejlertsen B
AU  - Delaloge S
AU  - Moy B
AU  - Iwata H
AU  - von Minckwitz G
AU  - Mansi J
AU  - Barrios CH
AU  - Gnant M
AU  - Tomašević Z
AU  - Denduluri N
AU  - Šeparović R
AU  - Kim SB
AU  - Jakobsen EH
AU  - Harvey V
AU  - Robert N
AU  - Smith J 2nd
AU  - Harker G
AU  - Zhang B
AU  - Eli LD
AU  - Ye Y
AU  - Lalani AS
AU  - Buyse M
AU  - Chan A
PY  - 2019
JO  - Breast cancer research : BCR
DO  - 10.1186/s13058-019-1115-2
UR  - https://doi.org/10.1186/s13058-019-1115-2
ER  -

APA

SKL, C., M, M., FA, H., B, E., S, D., B, M., H, I., G, V. M., J, M., CH, B., M, G., Z, T., N, D., R, Š., SB, K., EH, J., V, H., N, R., 2nd, S. J., G, H., B, Z., LD, E., Y, Y., AS, L., M, B., & A, C. (2019). PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.. Breast cancer research : BCR. https://doi.org/10.1186/s13058-019-1115-2

Source records

pubmed · retrieved 2026-09-26T18:51:04.511Z